费城 - 专注于实体肿瘤T细胞双特异性抗体的临床阶段生物制药公司Context Therapeutics Inc. (NASDAQ: CNTX )宣布，任命Karen Chagin博士为新任首席医疗官 (CMO)，自2025年6月9日起生效。拥有超过十年行业经验的Chagin博士将接替担任临时CMO的Karen Smith博士，后者将继续担任公司董事会成员。根据 InvestingPro 数据显示 ...

周二，Citizens JMP分析师维持Context Therapeutics股票 (NASDAQ: CNTX )的"市场表现优于大盘"评级，目标价为4.00美元，较当前0.59美元的价格有显著上涨空间。该股票交易价格远低于分析师4.00美元至9.00美元的更广泛目标区间。分析师在与公司新任首席医疗官Karen ...

Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T ...

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company ...

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer (CMO), effective June 9, 2025. Dr. Chagin will succeed ...

There are very few people who understand the Dakar like Kamaz Master team boss Vladimir Chagin. When it comes to desert racing, the man is an absolute legend, having won the Dakar an incredible ...

Autophagy, a mechanism of organelle recycling that promotes cell survival, has been previously implicated in osteoarthritis (OA). One of the proteins fundamental to this process, autophagy protein ...

View Full Profile. Learn about our Editorial Policies. To explore this question, Chagin and his team sequenced human embryonal facial material to look for active enhancer elements. They identified the ...